Lung cancer in scleroderma: Results from an Italian rheumatologic center and review of the literature

Autoimmunity Reviews

Volumn 12, Issue 3, 2013, Pages 374-379

  Colaci, Michele ^a,b   Giuggioli, Dilia ^a,b   Sebastiani, Marco ^a,b   Manfredi, Andreina ^a,b   Vacchi, Caterina ^a,b   Spagnolo, Paolo ^a,b   Cerri, Stefania ^a,b   Luppi, Fabrizio ^a,b   Richeldi, Luca ^a,b   Ferri, Clodoveo ^a,b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Carcinoma; Lung cancer; Scleroderma; Systemic sclerosis

Indexed keywords

CYCLOPHOSPHAMIDE; SCL 70 ANTIBODY;

ADULT; AGED; CANCER MORTALITY; CANCER PATIENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; FORCED VITAL CAPACITY; HUMAN; ITALY; LUNG CANCER; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; PREVALENCE; RETROSPECTIVE STUDY; REVIEW; SCLERODERMA; SEX DIFFERENCE;

ADULT; AGED; AUTOANTIBODIES; FEMALE; HUMANS; INCIDENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC;

EID: 84872424442     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.06.003     Document Type: Review

References (40)

1. Leandro M.J., Isenberg D.A. Rheumatic diseases and malignancy-is there an association?. Scand J Rheumatol 2001, 30:185-188.
2. Caldwell D.S., McCallum R.M. Rheumatologic manifestations of cancer. Med Clin North Am 1986, 70:385-417.
3. Prete M., Racanelli V., Digiglio L., Vacca A., Dammacco F., Perosa F. Extra-articular manifestations of rheumatoid arthritis: an update. Autoimmun Rev 2011, 11:123-131.
4. Anaya J.M., Shoenfeld Y., Cervera R. Facts and challenges for the autoimmunologist. Lessons from the second Colombian autoimmune symposium. Autoimmun Rev 2012, 11:249-251.
5. Ferri C., Valentini G., Cozzi F., Sebastiani M., Michelassi C., La Montagna G., et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine 2002, 81:139-153.
6. Marasini B., Conciato L., Belloli L., Massarotti M. Systemic sclerosis and cancer. Int J Immunopathol Pharmacol 2009, 22:573-578.
7. Wooten M. Systemic sclerosis and malignancy: a review of the literature. South Med J 2008, 101:59-62.
8. Steen V.D., Medsger T.A. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007, 66:940-944.
9. Nannini C., West C.P., Erwin P.J., Matteson E.L. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 2008, 10:R124.
10. Friedman G.D., Jiang S.F., Udaltsova N., Quesenberry C.P., Chan J., Habel L.A. Epidemiologic evaluation of pharmaceuticals with limited evidence of carcinogenicity. Int J Cancer 2009, 125:2173-2178.
11. Colaci M., Sebastiani M., Giuggioli D., Manfredi A., Spagnolo P., Luppi F., et al. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma alveolitis. Scand J Rheumatol 2010, 39:155-159.
12. New incidence and mortality data 2003-2005. Epidemiol Prev 2009, 33(Suppl. 2). AIRTUM Working Group.
13. Hesselstrand R., Scheja A., Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998, 57:682-686.
14. Peters-Golden M., Wise R.A., Hochberg M., Stevens M.B., Wigley F.M. Incidence of lung cancer in systemic sclerosis. J Rheumatol 1985, 12:1136-1139.
15. Roumm A.D., Medsger T.A. Cancer and systemic sclerosis. An epidemiologic study. Arthritis Rheum 1985, 28:1336-1340.
16. Rothfield N., Kurtzman S., Vasques-Abal D., Charron C., Daniels L., Greenberg B. Association of antitopoisomerase 1 with cancer. Arthritis Rheum 1992, 35:724.
17. Abu-Shakra M., Guillemin F., Lee P. Cancer in systemic sclerosis. Arthritis Rheum 1993, 36:460-464.
18. Rosenthal A.K., McLaughlin J.K., Linet M.S., Persson I. Scleroderma and malignancy: an epidemiological study. Ann Rheum Dis 1993, 52:531-533.
19. Rosenthal A.K., McLaughlin J.K., Gridley G., Nyrén O. Incidence of cancer among patients with systemic sclerosis. Cancer 1995, 76:910-914.
20. Nishioka K., Katayama I., Kondo H., Shinkai H., Ueki H., Tamaki K., et al. Epidemiological analysis of prognosis of 496 Japanese patients with progressive systemic sclerosis (SSc). Scleroderma Research Committee Japan. J Dermatol 1996, 23:677-682.
21. Kyndt X., Hebbar M., Queyrel V., Hachulla E., Hatron P.Y., Devulder B. Sclérodermie systémique et cancer. Recherche de facteurs prédictifs de cancer chez 123 patients sclérodermiques. Rev Med Interne 1997, 18:528-532.
22. Hill C.L., Nguyen A.M., Roder D., Robert-Thomson P. Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis 2003, 62:728-731.
23. Chatterjee S., Dombi G.W., Severson R.K., Mayes M.D. Risk of malignancy in scleroderma. A population-base color study. Arthritis Rheum 2005, 52:2415-2424.
24. Kang K.Y., Yim H.W., Kim I.J., Yoon J.U., Ju J.H., Kim H.Y., et al. Incidence of cancer among patients with systemic sclerosis in Korea: results from a single centre. Scand J Rheumatol 2009, 38:299-303.
25. Siau K., Laversuch C.J., Creamer P., O'Rourke K.P. Malignancy in scleroderma patients from south west England: a population-based cohort study. Rheumatol Int 2011, 31:641-645.
26. Joven B.E., Fare R., Colina F., Ramos B., Carreira P.E. Cancer incidence in systemic sclerosis in Spain: results from a single University Hospital. Ann Rheum Dis 2009, 68(Suppl. 3):272.
27. Olesen A.B., Svaerke C., Farkas D.K., Sørensen H.T. Systemic sclerosis and the risk of cancer: a nationwide population-based cohort study. Br J Dermatol 2010, 163:800-806.
28. Szekanecz E., Szamosi S., Horvàth A., Németh A., Juhàsz B., Szàntò J., et al. Malignancies associated with systemic sclerosis. Autoimmun Rev 2012, 11(12):852-855.
29. Kuo C.F., Luo S.F., Yu K.H., Chou I.J., Tseng W.Y., Chang H.C., et al. Cancer risk among patients with systemic sclerosis: a nationwide population study in Taiwan. Scand J Rheumatol 2012, 41:44-49.
30. Arnson Y., Amital H., Agmon-Levin N., Alon D., Sánchez-Castañón M., López-Hoyos M., et al. Serum 25-OH vitamin D concentrations are linked with various clinical aspects in patients with systemic sclerosis: A retrospective cohort study and review of the literature. Autoimmun Rev 2011, 10:490-494.
31. Cutolo M., Pizzorni C., Sulli A. Vitamin D endocrine system involvement in autoimmune rheumatic diseases. Autoimmun Rev 2011, 11:84-87.
32. Higuchi M., Horiuchi T., Ishibashi N., Yoshizawa S., Niho Y., Nagasawa K. Anticentromere antibody as a risk factor for cancer in patients with systemic sclerosis. Clin Rheumatol 2000, 19:123-126.
33. Perera A., Fertig N., Lucas M., Rodriguez-Reyna T.S., Hu P., Steen V.D., et al. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody. Arthritis Rheum 2007, 56:2740-2746.
34. Hamaguchi Y. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis. J Dermatol 2010, 37:42-53.
35. Marie I., Josse S., Decaux O., Dominique S., Diot E., Landron C. Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev 2012, 11(10):739-745.
36. Daniels C.E., Jett J.R. Does interstitial lung disease predispose to lung cancer?. Curr Opin Pulm Med 2005, 11:431-437.
37. Pontifex E.K., Hill C.L., Roberts-Thomson P. Risk factors for lung cancer in patients with scleroderma: a nested case-control study. Ann Rheum Dis 2007, 66:551-553.
38. Centers for Disease Control and Prevention (CDC). The impact of smoking on diseases and the benefits of smoking reduction. accessed June 5, 2011. http://www.cdc.gov/tobacco/data_statistics/sgr/2004/pdfs/chapter7.pdf.
39. Sakkas L.I., Moore D.F., Akritidis N.C. Cancer in families with systemic sclerosis. Am J Med Sci 1995, 310:223-225.
40. Diot E., Lesire V., Guilmot J.L., Metzger M.D., Pilore R., Rogier S., et al. Systemic sclerosis and occupational risk factors: a case-control study. Occup Environ Med 2002, 59:545-549.